News blog
Alliance Pharma
- BY: Andrew Hore |
- POSTED: 16/05/2008 |
- COMMENTS: Add yours
Alliance Pharma’s new product Isprelor’s trial results are likely to be disappointing.
Isprelor has been developed to induce labour in pregnant women. Alliance has decided to re-evaluate its development plan for Isprelor because the results of the phase III trials won’t be good enough to support an application for registration.
The additional work required for filing for registration means that this probably won’t happen before 2011.
Alliance shares fell 0.25p to 8.375p, valuing the company at £14m.
© 2007 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- 2.4mNumber of messages posted on SocialGo networks
- $38mCost savings generated by ideas from WalMart staff over a two month period
- 19.4m
Number of people passing through Johannesburg Airport in 2007
- News Blog
- All micro news
Sanderson Group
Enterprise software provider Sanderson Group is continuing to benefit from growth in multi-channel retailing.
Resources In Insurance Group
Claims management services provider Resources In Insurance Group has slashed its loss in 2011.
atUK
e-commerce services provider @UK has gained a four year national e-commerce framework agreement for all UK public bodies.
Hydrogen Group
Recruitment firm Hydrogen Group says that net fee income for the first four months of 2012 was higher than the same period last year.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|